DE3679955D1 - ((2,3,9,9a-tetrahydro-3-oxo-9a-substituierte-1h-fluoren-7-yl)-oxy)ethanimidamide und ((2,3,9,9a-tetrahydro-3-oxo-9a-substituierte-1h-fluoren-7-yl)-oxy)ethanimidsaure hydrazide, ihre derivate und salze. - Google Patents

((2,3,9,9a-tetrahydro-3-oxo-9a-substituierte-1h-fluoren-7-yl)-oxy)ethanimidamide und ((2,3,9,9a-tetrahydro-3-oxo-9a-substituierte-1h-fluoren-7-yl)-oxy)ethanimidsaure hydrazide, ihre derivate und salze.

Info

Publication number
DE3679955D1
DE3679955D1 DE8686113183T DE3679955T DE3679955D1 DE 3679955 D1 DE3679955 D1 DE 3679955D1 DE 8686113183 T DE8686113183 T DE 8686113183T DE 3679955 T DE3679955 T DE 3679955T DE 3679955 D1 DE3679955 D1 DE 3679955D1
Authority
DE
Germany
Prior art keywords
sup
fluoren
tetrahydro
oxy
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686113183T
Other languages
English (en)
Inventor
Edward J Cragoe
Otto W Woltersdorf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE3679955D1 publication Critical patent/DE3679955D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
DE8686113183T 1985-09-26 1986-09-25 ((2,3,9,9a-tetrahydro-3-oxo-9a-substituierte-1h-fluoren-7-yl)-oxy)ethanimidamide und ((2,3,9,9a-tetrahydro-3-oxo-9a-substituierte-1h-fluoren-7-yl)-oxy)ethanimidsaure hydrazide, ihre derivate und salze. Expired - Fee Related DE3679955D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/780,145 US4604396A (en) 1985-09-26 1985-09-26 [(2,3,9,9a-tetrahydro-3-oxo-9a-substituted-1H-fluoren-7-yl)oxy]ethanimidamides and [(2,3,9,9a-tetrahydro-3-oxo-9a-substituted-1H-fluoren-7-yl)oxy]ethanimidic acid hydrazides, their derivatives and their salts

Publications (1)

Publication Number Publication Date
DE3679955D1 true DE3679955D1 (de) 1991-08-01

Family

ID=25118757

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686113183T Expired - Fee Related DE3679955D1 (de) 1985-09-26 1986-09-25 ((2,3,9,9a-tetrahydro-3-oxo-9a-substituierte-1h-fluoren-7-yl)-oxy)ethanimidamide und ((2,3,9,9a-tetrahydro-3-oxo-9a-substituierte-1h-fluoren-7-yl)-oxy)ethanimidsaure hydrazide, ihre derivate und salze.

Country Status (8)

Country Link
US (1) US4604396A (de)
EP (1) EP0217287B1 (de)
JP (1) JPS6284052A (de)
AT (1) ATE64733T1 (de)
CA (1) CA1284329C (de)
DE (1) DE3679955D1 (de)
DK (1) DK457286A (de)
ES (1) ES2001801A6 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797391A (en) * 1986-09-24 1989-01-10 Merck & Co., Inc. ((5,6-dichloro-3-oxo-9,9a-disubstituted-2,3,9,9a-tetrahydrofluoren-7-yl)oxy)alkanoic acids and alkanimidamides
US4769370A (en) * 1986-09-24 1988-09-06 Merck & Co., Inc. (1,2-dichloro-8-oxo-5a-substituted-5a,6,7,8-tetrahydrodibenzofuran-3-yl)alkanoic acids and alkanimidamides
US4731471A (en) * 1986-11-03 1988-03-15 Merck & Co., Inc. (5,6-dichloro-3-oxo-2,3,9,9a-tetrahydrofluoren-7-yl)-alkanoic acids and alkanimidamides bearing novel functional 9a-substituents
US4782073A (en) * 1986-12-24 1988-11-01 Merck & Co., Inc. Amides of [(5,6-dichloro-3-oxo-9-alpha-substituted-2,3,9,9-alpha-tetrahydrofluoren-7-yl-oxyl]acetic acids, and pharmaceutical compositions thereof
US4771076A (en) * 1987-06-01 1988-09-13 Merck & Co., Inc. [(2-substituted 1,2-dihydro-1-oxo-1H-inden-5-yl)oxy]alkanesulfonic acids and salts thereof
US4775695A (en) * 1987-06-01 1988-10-04 Merck & Co., Inc. Substituted amidinoalkoxy and amidinoalkylamino indanones and salts thereof
JP4674339B2 (ja) * 1998-08-07 2011-04-20 三菱化学株式会社 脳損傷の予防・治療剤
US6251898B1 (en) * 1999-08-24 2001-06-26 Questcor Pharmaceuticals, Inc. Medical use of fluorenone derivatives for treating and preventing brain and spinal injury
ATE524170T1 (de) * 2000-02-14 2011-09-15 Merck Sharp & Dohme Östrogenrezeptor modulatoren
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
AR051597A1 (es) * 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
BR112015014178A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida
BR112015014349A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por hidratação mucosa insuficiente
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
CN110054580A (zh) * 2019-05-22 2019-07-26 苏州百灵威超精细材料有限公司 4-(4-n-马来酰亚胺苯基)丁酸酰肼盐酸盐的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317922A (en) * 1979-10-19 1982-03-02 Merck & Co., Inc. [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids and their analogs, esters, salts and derivatives
US4337354A (en) * 1979-10-19 1982-06-29 Merck & Co., Inc. [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids, their analogs, esters, salts, and derivatives
US4356313A (en) * 1979-10-19 1982-10-26 Merck & Co., Inc. [(5,6,9a-substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acid esters and their analogs, the parent acids and their salts
GR70295B (de) * 1979-10-19 1982-09-06 Merck & Co Inc
US4356314A (en) * 1980-06-30 1982-10-26 Merck & Co., Inc. [5,6,9A-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids, their analogs, esters, salts, and derivatives
US4316043A (en) * 1980-12-19 1982-02-16 Merck & Co., Inc. [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids and their analogs, esters, salts and derivatives

Also Published As

Publication number Publication date
DK457286D0 (da) 1986-09-25
EP0217287B1 (de) 1991-06-26
EP0217287A3 (en) 1988-07-20
JPS6284052A (ja) 1987-04-17
ES2001801A6 (es) 1988-06-16
DK457286A (da) 1987-03-27
CA1284329C (en) 1991-05-21
US4604396A (en) 1986-08-05
EP0217287A2 (de) 1987-04-08
ATE64733T1 (de) 1991-07-15

Similar Documents

Publication Publication Date Title
DE3679955D1 (de) ((2,3,9,9a-tetrahydro-3-oxo-9a-substituierte-1h-fluoren-7-yl)-oxy)ethanimidamide und ((2,3,9,9a-tetrahydro-3-oxo-9a-substituierte-1h-fluoren-7-yl)-oxy)ethanimidsaure hydrazide, ihre derivate und salze.
FI892787A0 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 1-indolyylialkyyli-4-(substituoitu pyridinyyli)piperatsiinien valmistamiseksi
NO171785C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinazolinderivater
NO163819C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1h-imidazo(4,5-c)kinolin og derivater derav.
MX9306831A (es) Nuevos compuestos heterociclicos.
MY101208A (en) Phenyl-piperazine anti-arrhythmia agents.
IL103944A0 (en) Piperazine derivatives,their preparation and pharmaceutical compositions containing them
NO892058D0 (no) Fremgangsnaate for fremstilling av terapeutisk aktive benzamider.
FI894693A0 (fi) Menetelmä valmistaa farmaseuttisesti arvokasta imidatsoliinijohdannaista
ES8404980A1 (es) Un procedimiento para preparar guanidino-fenilamidinas heterociclicas sustituidas.
GB2254324B (en) Piperazine derivatives
ES471895A1 (es) Procedimiento para preparar derivados de benzamidina
DE3271277D1 (en) Tropyl and pseudotropyl alkyl-benzoates and their use in migraine treatment
HUP9900895A2 (hu) Simaizom sejtburjánzást gátló 2-szubsztituált benzimidazolszármazékok
DK0658555T3 (da) Pyridazinonderivater, fremgangsmåder til fremstilling deraf samt anvendelse deraf
ES527842A0 (es) Procedimiento para preparar derivados de benzoato de propilo o pseudopropilo

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee